Search

Displaying results 3561 - 3570 of 10000 in total
  1. Drug

    Aleglitazar

    go.drugbank.com/drugs/DB08915
    Investigational

    In the phase II clinical trial called SYNCHRONY, with type II diabetic patients, aleglitazar was able to control both lipid and glucose levels in a synergistic manner while also having limited side effects … Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO.

  2. Drug

    Temocapril

    go.drugbank.com/drugs/DB08836
    Investigational

    Temocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States, but is approved in Japan and South Korea. … Temocapril can also be used in hemodialysis patients without risk of serious accumulation.

    Categories: Agents Acting on the Renin-Angiotensin System
  3. Drug

    Pegaptanib

    go.drugbank.com/drugs/DB04895
    ApprovedWithdrawn

    Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. … Pegaptanib was granted FDA approval on 17 September 2004.[L17903]

  4. Drug

    Bepotastine

    go.drugbank.com/drugs/DB04890
    Approved

    It is available in oral and opthalmic dosage forms in Japan. The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve. … Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the

  5. Drug

    Quercetin

    go.drugbank.com/drugs/DB04216
    Investigational

    Quercetin is a flavonol widely distributed in plants. It is an antioxidant, like many other phenolic heterocyclic compounds. Glycosylated forms include RUTIN and quercetrin.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    CHGN111

    go.drugbank.com/drugs/DB06376
    Experimental

    Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative … CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase.

  7. Drug

    Cefroxadine

    go.drugbank.com/drugs/DB11367
    ApprovedWithdrawn

    It was used in Italy but has since been withdrawn. … Cefroxadine is an orally available cephalosporin antibiotic. As part of its drug class, it shares structural properties to [cefalexin] as well as its activity spectrum.

  8. Drug

    Carindacillin

    go.drugbank.com/drugs/DB09319
    ApprovedWithdrawn

    Carindacillin or Carbenicillin isdanyl was an oral penicillin prodrug of [carbenicillin] marketed by Pfizer as Geocillin. It is no longer marketed in the United States.

  9. Drug

    Sibutramine

    go.drugbank.com/drugs/DB01105
    ApprovedIllicitWithdrawn

    Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. … It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States.

  10. Drug

    Atrazine

    go.drugbank.com/drugs/DB07392
    Experimental

    Atrazine is a selective triazine herbicide. Inhalation hazard is low and there are no apparent skin manifestations or other toxicity in humans.

    Categories: Compounds used in a research, industrial, or household setting